Prosecution Insights
Last updated: November 04, 2026
Application No. 18/400,666

DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS

Non-Final OA §101§112
Filed
Dec 29, 2023
Priority
Oct 01, 2007 — provisional 60/997,334 +5 more
Examiner
OUSPENSKI, ILIA I
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Seattle Children'S Hospital
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
877 granted / 1133 resolved
+17.4% vs TC avg
Strong +20% interview lift
Without
With
+20.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
47 currently pending
Career history
1188
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
9.5%
-30.5% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
38.4%
-1.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1133 resolved cases

Office Action

§101 §112
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. Applicant's preliminary amendment filed on 03/18/2024 is acknowledged. Claims 40-54 are pending. 3. 35 U.S.C. § 101 reads as follows: "Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title". 4. Claim 40-54 rejected under 35 U.S.C. 101 because the claimed invention is directed to judicial exceptions, i.e. an abstract idea and a law of nature, without significantly more. The claims recite mental processes of “distinguishing,” comparing (“amount that is lower than a control value”), and reaching a conclusion (“”value is indicative of”). If a claim limitation covers performance of the limitation in the mind, then it falls within the “Mental Processes” grouping of abstract ideas. Accordingly, the claim recites an abstract idea. The claims also recite a law of nature or a natural phenomenon, i.e. a naturally occurring correlation between circulating PD-L1 amount and the state of autoimmune disease. The claims do not integrate the abstract idea or law of nature into a practical application because the claims are directed to a method of “distinguishing” between states of autoimmune disease, which is not a practical application. The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception. The step of “determining the amount of circulating PD-L1 in a blood sample obtained from the human subject by contacting the blood sample with a detectably labeled antibody specific for PD-L1” is a data gathering step required to use the naturally occurring correlation does not add a meaningful limitation to the method because it is well-understood, routine, and conventional. Therefore, this step is not sufficient to amount to significantly more than the judicial exception. Consequently, the claims are not patent eligible. 5. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION. —The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. 6. Claims 41-54 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. (i) Claim 40 is indefinite in the recitation of a “control value” of circulating PD-L1, because the value is unknown. (ii) Claim 45 is indefinite, because it is unknown how the recited additional step of “contacting” relates to “distinguishing” the states of autoimmune disease. (iii) Claim 48 is indefinite, because the recitation of “the APC” lacks proper antecedent basis in the base claim. (iv) Claim 51 is indefinite, because it is unknown how the control value is “established based on” the PD-L1 level of one or more healthy subjects. (v) Claims 42-54 are indefinite, because they encompass the indefinite limitations of the claim(s) on which they depend. In view of the above, a person of ordinary skill in the art cannot unequivocally interpret the metes and bounds of the claims so as to understand how to avoid infringement. Applicant is reminded that any amendment must point to a basis in the specification so as not to add New Matter. See MPEP 714.02 and 2163.06. 7. The following is a quotation of 35 U.S.C. 112(d): REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. 8. Claim 41 is rejected under 35 U.S.C. 112(d) as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 41 depends on claim 40 which is limited to autoimmune disease, whereas claim 41 encompasses transplant rejection which is not an autoimmune disease. Therefore, dependent claim 41 may be infringed without infringing the base claim, and as such, claim 41 fails to further limit, and fails to include all the limitations of the claim upon which it depends. Applicant may cancel the claim, amend the claim to place it in proper dependent form, rewrite the claim in independent form, or present a sufficient showing that the dependent claim complies with the statutory requirements. 9. The following US Patents share a coinventor and/or an assignee with the present application, and claim subject matter similar to that of the present claims, but do not contain patented claims which would anticipate or make obvious the presently claimed invention: US 8062852 (IDS), US 9168296 (IDS), US 10371702, US 11860161. 10. Conclusion: no claim is allowed. 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ILIA I OUSPENSKI whose telephone number is (571)272-2920. The examiner can normally be reached 9 AM - 5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ILIA I OUSPENSKI/ Primary Examiner, Art Unit 1644
Read full office action

Prosecution Timeline

Dec 29, 2023
Application Filed
Mar 18, 2024
Response after Non-Final Action
Oct 27, 2026
Non-Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780927
COMPOSITIONS AND METHODS FOR TREATING NONINFLAMMATORY PAIN IN SUBJECTS WITH RHEUMATOID ARTHRITIS
3y 4m to grant Granted Nov 03, 2026
Patent 12780894
PD1-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF
3y 4m to grant Granted Nov 03, 2026
Patent 12774333
COMPOSITIONS AND METHODS FOR MAKING AND USING MULTISPECIFIC ANTIBODIES
4y 8m to grant Granted Oct 27, 2026
Patent 12767699
PD-L1 variants with improved affinity towards PD-1
3y 11m to grant Granted Oct 20, 2026
Patent 12766193
ANTI-CD133 SINGLE-CHAIN ANTIBODY AND USE THEREOF IN PREPARATION OF DRUG FOR TREATING TUMOR
3y 8m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
98%
With Interview (+20.5%)
2y 8m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1133 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month